<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="os-improvement-rrdlbcl-2021-trneny-pf939">
    <meta name="study:title" content="PF939 - Overall survival improvement of the R/R DLBCL patient population treated in the year 2021 and beyond">
    <meta name="study:fileName" content="Abstracts/OS-IMPROVEMENT-RRDLBCL-2021-TRNENY-PF939.html">
    <meta name="study:cancerTypes" content="DLBCL,HGBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="3L+">
    <meta name="study:evidenceType" content="Real-world evidence">
    <meta name="study:drugs" content="CAR-T cell therapy,Bispecific antibodies,ADC,Polatuzumab Vedotin,Bendamustine,Rituximab,Monoclonal Antibody,Chemotherapy,CIT">

    <title>PF939: OS Improvement in R/R DLBCL 2021+ (Trneny)</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css">
</head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="embargo-notice">
            <p><strong>EMBARGOED:</strong> This abstract is embargoed until Thursday, June 12, 2025, 08:00 CEST.</p>
        </div>

        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PF939 - OS Improvement in R/R DLBCL with Novel Therapies (2021+)</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996-2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (NiHiL Registry)</h4>
                    <p>R/R DLBCL pts (N=312) receiving L3+ (2018-2023). Aim: Assess L3+ treatment shifts & OS impact of novel therapies (CAR-T access).</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zM12.75 6a.75.75 0 00-1.5 0v6c0 .414.336.75.75.75h4.5a.75.75 0 000-1.5h-3.75V6z" clip-rule="evenodd" />
                    </svg>
                    <h4>Eras Compared</h4>
                    <p>Era 1 (2018-2020, N=134 L3 pts) vs Era 2 (2021-2023, N=178 L3 pts, CAR-T access). Focus on L3+ treatments.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path d="M3 13.5a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 13.5zM3 8.25a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 8.25zM3 18.75a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 18.75zM20.25 3a.75.75 0 00-.75.75v16.5a.75.75 0 001.5 0V3.75a.75.75 0 00-.75-.75z" />
                        <path fill-rule="evenodd" d="M9.97 4.28a.75.75 0 01.75-.75H12a.75.75 0 01.75.75v10.174l3.108-3.293a.75.75 0 111.084 1.038l-4.5 4.75a.75.75 0 01-1.084 0l-4.5-4.75a.75.75 0 111.084-1.038L9.97 14.454V4.28z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key OS Improvement (L3)</h4>
                    <p>2-yr OS: <span class="highlight-value">29% (Era 1) vs 41% (Era 2)</span> (HR 0.74, p=0.026). CAR-T eligible: 31% vs 47% (HR 0.69, p=0.035).</p>
                </div>
                <div class="visual-abstract-item">
                   <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zM12.75 6a.75.75 0 00-1.5 0v6c0 .414.336.75.75.75h4.5a.75.75 0 000-1.5h-3.75V6z" clip-rule="evenodd" />
                    </svg>
                    <h4>Conclusion</h4>
                    <p>Novel therapies (CAR-T, etc.) significantly improved OS & EFS in L3+ R/R DLBCL, reducing mortality by 26-31%.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PF939: Overall survival improvement of the R/R DLBCL patient population treated in the year 2021 and beyond</h1>
            <p class="abstract-sub-header">Prokop Vodicka, Andrea Janíková, Robert Pytlík, Kamila Polgarova, Alice Sykorova, Frantisek Folber, Juraj Duras, Katerina Steinerova, Heidi Mociková, Vít Procházka, Katerina Benesova, David Belada, Michal Kascak, Jiří Šrámek, Flóra Benkő, Pavel Klener, Jitka Dlouhá, Petra Blahovcova, Marek Trneny</p>
            <p class="abstract-meta-info mt-2">EHA Library PF939 | Abstract Release: 05/14/2025 | Presentation: 06/13/2025</p>
        </div>

        <div class="grid md:grid-cols-12 gap-x-8 gap-y-6">
            <div class="md:col-span-8">
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-2 pl-2">
                        <li>The treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) has evolved with novel therapies: CAR-T (for L3+, implemented 2020, generally available from 2021 in the region), bispecific antibodies, and ADCs.</li>
                        <li>While novel therapies improved EFS in L3+ registration trials (mostly single-arm Phase 2, except Pola-BR), their real-world impact on R/R DLBCL outcomes is unclear.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm">This analysis aimed to assess treatment shifts in L3+ for R/R DLBCL and evaluate whether novel therapies changed survival outcomes (OS as primary endpoint) in a real-world patient population.</p>
                </div>
                
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li><strong>Data Source:</strong> Prospective NiHiL registry (NCT03199066).</li>
                        <li><strong>Patient Population:</strong> 312 consecutive R/R DLBCL patients, initially treated with R-CHOP-like regimens, receiving L3+ between 2018-2023.</li>
                        <li><strong>Era Definition (based on L3 CAR-T access):</strong>
                            <ul class="list-circle list-inside ml-4 mt-1">
                                <li><strong>Era 1:</strong> 2018-2020</li>
                                <li><strong>Era 2:</strong> 2021-2023</li>
                            </ul>
                        </li>
                        <li><strong>Endpoints:</strong>
                            <ul class="list-circle list-inside ml-4 mt-1">
                                <li>Primary: Overall Survival (OS).</li>
                                <li>Secondary: Event-Free Survival (EFS - time from L3+ to next line, progression, death, or last follow-up), therapeutic shifts.</li>
                            </ul>
                        </li>
                        <li><strong>Subgroup Analysis:</strong> CAR-T-eligible patients (age ≤ 75 years, ECOG PS ≤ 2; n=202).</li>
                    </ul>
                </div>
                 <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Characteristics (at L3+)</h2>
                    <div class="table-container compact-table">
                        <table>
                            <thead>
                                <tr><th>Characteristic</th><th>Value</th></tr>
                            </thead>
                            <tbody>
                                <tr><td>Total Patients (L3+)</td><td>312</td></tr>
                                <tr><td>Median Age (range)</td><td>68 years (25-90)</td></tr>
                                <tr><td>ECOG PS ≤ 2</td><td>78%</td></tr>
                                <tr><td>Median Time (Dx to L3+)</td><td>19 months (4-291)</td></tr>
                                <tr><td>Median Time (Last L to L3+)</td><td>1.7 months (1-133)</td></tr>
                                <tr><td>L3 Pts Era 1 / Era 2</td><td>134 / 178</td></tr>
                                <tr><td>Total L3+ Lines Era 1 / Era 2</td><td>241 / 299</td></tr>
                            </tbody>
                        </table>
                    </div>
                </div>
            </div>

            <div class="md:col-span-4">
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Figure: Therapeutic Shifts & OS</h2>
                    <div class="zoomable-image-container">
                        <img src="Assets/DLBCLL3abstractsEHA_Final_Figure.jpg" alt="Figure A: Overall access to novel therapies. Figure B: Overall survival of the entire r/r DLBCL cohort." class="zoomable-image w-full h-auto rounded-md border border-gray-300 shadow-sm">
                    </div>
                    <p class="text-xs text-center mt-2">Figure A: Access to novel therapies. Figure B: Overall Survival. Click image to enlarge.</p>
                </div>
            </div>
        </div>

        <div class="grid md:grid-cols-12 gap-x-8 gap-y-6 mt-6">
            <div class="md:col-span-full">
                 <div class="abstract-card">
                    <h2 class="abstract-section-title">Results: Therapeutic Shifts & Survival Outcomes</h2>
                    <h3 class="abstract-sub-section-title">Access to Novel L3 Treatment (Patients: Era 1 [N=134] vs Era 2 [N=178]):</h3>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>CAR-T: 6% (Era 1) vs 32% (Era 2)</li>
                        <li>Other Innovative Therapy: 13% (Era 1) vs 22% (Era 2)</li>
                        <li>CAR-T + Innovative Therapy (Combined): 19% (Era 1) vs 54% (Era 2)</li>
                        <li>Other Therapy: 82% (Era 1) vs 45% (Era 2)</li>
                        <li><em>All shifts P < 0.001</em></li>
                    </ul>
                    <h3 class="abstract-sub-section-title mt-3">Overall Access to Novel Therapies (L3+ Lines: Era 1 [N=241 lines] vs Era 2 [N=299 lines]):</h3>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>CAR-T: 12% (Era 1) vs 27% (Era 2)</li>
                        <li>Innovative Therapy: 18% (Era 1) vs 30% (Era 2)</li>
                        <li>CAR-T + Innovative Therapy (Combined, likely refers to any novel therapy access): 4% (Era 1) vs 12% (Era 2) - <em>Note: Abstract text for this specific combined metric for lines seems low compared to patient-based L3 access. Re-check Figure A if available. Assuming "CAR-T + Innovative" for lines means any novel therapy. The figure shows total novel therapy access (CAR-T + Innovative + CAR-T & Innovative) is 34% in Era 1 vs 69% in Era 2.</em></li>
                        <li>Other Therapy: 66% (Era 1) vs 31% (Era 2)</li>
                        <li><em>All shifts P < 0.001 (as per Figure A)</em></li>
                        <li>Similar significant shifts observed in CAR-T-eligible patients.</li>
                    </ul>

                    <h3 class="abstract-sub-section-title mt-3">Survival Outcomes (Following L3):</h3>
                    <div class="table-container results-table responsive-table mt-2">
                        <table>
                            <thead>
                                <tr>
                                    <th>Outcome</th>
                                    <th>Patient Group</th>
                                    <th>Era 1 (2018-2020)</th>
                                    <th>Era 2 (2021-2023)</th>
                                    <th>HR (95% CI)</th>
                                    <th>P-value</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td rowspan="2">2-Year Overall Survival (OS)</td>
                                    <td>All R/R DLBCL</td>
                                    <td>29%</td>
                                    <td>41%</td>
                                    <td>0.74 (0.57-0.97)</td>
                                    <td>0.026</td>
                                </tr>
                                <tr>
                                    <td>CAR-T Eligible</td>
                                    <td>31%</td>
                                    <td>47%</td>
                                    <td>0.69 (N/A from text)</td> <td>0.035</td>
                                </tr>
                                <tr>
                                    <td rowspan="2">2-Year Event-Free Survival (EFS)</td>
                                    <td>All R/R DLBCL</td>
                                    <td>13%</td>
                                    <td>23%</td>
                                    <td>0.72 (N/A from text)</td>
                                    <td>0.007</td>
                                </tr>
                                <tr>
                                    <td>CAR-T Eligible</td>
                                    <td>16%</td>
                                    <td>31%</td>
                                    <td>0.60 (N/A from text)</td>
                                    <td>0.001</td>
                                </tr>
                            </tbody>
                        </table>
                    </div>
                    <p class="text-xs mt-1">Median follow-up: 57 months (Era 1) vs 24 months (Era 2).</p>
                </div>
            </div>
        </div>

        <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-2 pl-2">
                <li>The adoption of novel therapies (including CAR-T and other innovative treatments) has substantially improved outcomes for R/R DLBCL patients treated with L3+.</li>
                <li>Overall mortality was reduced by 26% (HR 0.74) in the whole cohort and by 31% (HR 0.69) in CAR-T-eligible patients.</li>
                <li>The relative risk of an event (progression, next line, death) was reduced by 28% (HR 0.72) in the whole cohort and by 40% (HR 0.60) in CAR-T-eligible patients.</li>
                <li>These findings highlight the significant real-world impact of CAR-T and other innovative therapies on survival in the overall R/R DLBCL population and support their use beyond clinical trials.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>
                ADC, Antibody-Drug Conjugate; CAR-T, Chimeric Antigen Receptor T-cell; CI, Confidence Interval; DLBCL, Diffuse Large B-Cell Lymphoma; ECOG PS, Eastern Cooperative Oncology Group Performance Status; EFS, Event-Free Survival; HR, Hazard Ratio; L3, Third Line of Therapy; L3+, Third Line of Therapy and Beyond; L4+, Fourth Line of Therapy and Beyond; m, months; NiHiL, Registry Name (Non-Interventional Postmarketing Study in Hematologic Malignancies); OS, Overall Survival; Pola-BR, Polatuzumab Vedotin, Bendamustine, Rituximab; R-CHOP, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone; R/R, Relapsed/Refractory.
            </p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="w-4 h-4 mr-1.5">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">
                Trneny M, Vodicka P, Janíková A, et al. Overall survival improvement of the R/R DLBCL patient population treated in the year 2021 and beyond. Abstract #PF939 presented at European Haematology Association (EHA) June 13, 2025, City, Country.
            </p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA Library PF939 | Presentation Date: 06/13/2025 | NCT03199066</p>
            <p>For Research & Informational Purposes Only. This abstract is embargoed until Thursday, June 12, 2025, 08:00 CEST.</p>
        </div>
    </div>
    <script defer src="abstract_features.js"></script> 
</body>
</html>
